Do not invest unless you are prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more.
Anne Dobrée, Investment Director at Parkwalk Advisors, recently joined Jonathan Moyes from Wealth Club to discuss all things EIS and university spinout investing. With her extensive experience, including her tenure as Head of Ventures at the University of Cambridge, Anne shared valuable insights into why spinout companies present unique investment opportunities.
Why Invest in University Spinouts?
University spinouts are startups formed to commercialize cutting-edge research from leading academic institutions. These companies often benefit from world-class intellectual property, strong founding teams, and access to deep networks of industry experts. Anne highlighted how spinouts have the potential to deliver high growth and impactful innovation, making them attractive for investors.
How Can Investors Back Spinouts Through EIS Funds?
For investors looking to support pioneering technology and benefit from significant tax incentives, the Enterprise Investment Scheme (EIS) offers a compelling route. Parkwalk’s EIS funds provide access to a diversified portfolio of high-growth spinout companies while delivering potential tax reliefs, such as income tax reduction and capital gains tax deferral.
Why Parkwalk?
Parkwalk Advisors is the UK’s leading investor in university spinouts, managing over £450 million in assets. Anne explained that Parkwalk’s expertise, deep university connections, and strong track record make it uniquely positioned to identify and invest in the most promising opportunities.
Recent Parkwalk Investments & Exits
Anne shared insights into some of Parkwalk’s exciting recent investments, including:
- AccelerComm – A deep-tech company optimizing 5G and satellite communications.
- PhoreMost – A biotech firm advancing drug discovery.
- Evoralis – A company driving innovation in sustainable chemistry.
She also discussed a maturing investment, Cytora, an AI-driven platform transforming insurance risk assessment, and notable exits such as:
Why Consider a Parkwalk EIS Fund?
Investing in a Parkwalk EIS fund provides access to high-growth, IP-rich companies with significant market potential. Additionally, the generous tax benefits associated with EIS make it a tax-efficient way to invest in innovation.
Parkwalk Advisors Limited (Parkwalk) is authorised and regulated by the Financial Conduct Authority: FRN 502237. Investments referred to in this news article are not suitable for all investors. Capital is at risk and investors may not get back the full amount invested. Any investment in a Parkwalk product must only be made on the basis of the terms of the full Information Memorandum. Tax treatment depends on the individual circumstances of each investor. Parkwalk is not able to provide advice as to the suitability of investing in any product. Past performance is not a reliable indicator of future results. This financial promotion was approved on 03/02/2025.
